Drug intelligence / Profile preview

RG-NAH005

Development stage: Preclinical
Lead developer: Regen BioPharma
Modality: Small Molecules

Overview

RG-NAH005 is a small molecule agonist of the nuclear receptor subfamily 2 group F member 6 (**NR2F6**), a transcription factor implicated in immune regulation. Developed by **Regen BioPharma**, it has demonstrated promising **ex-vivo** activity supporting advancement to animal models, with potential applications in **inflammatory bowel disease** (**IBD**) and other immune-mediated conditions through modulation of NR2F6 to enhance regulatory T-cell function or suppress excessive inflammation.[9][10][11]

Targets

NR2F6 (Nuclear receptor subfamily 2 group F member 6)

Beyond the preview

Go deeper on RG-NAH005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG-NAH005.

Explore the full profile